Michael Okunewitch
Stock Analyst at Maxim Group
(0.94)
# 3,808
Out of 4,954 analysts
27
Total ratings
29.17%
Success rate
-10.72%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.52 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $3.40 | +929.41% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $1.61 | - | 2 | May 23, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $6.67 | +79.91% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $0.91 | +672.80% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.72 | +713.95% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.19 | +152.10% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.01 | +296.04% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.57 | +2,005.26% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.80 | +650.00% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.80 | +1,401.13% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.30 | +1,746.15% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.65 | +579.25% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.26 | +89,501.77% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.44 | +43.35% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.48 | +304.31% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.97 | +529.72% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.23 | +8,063.27% | 1 | Nov 30, 2021 |
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.52
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $3.40
Upside: +929.41%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.61
Upside: -
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $6.67
Upside: +79.91%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $0.91
Upside: +672.80%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.72
Upside: +713.95%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.19
Upside: +152.10%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.01
Upside: +296.04%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.57
Upside: +2,005.26%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.80
Upside: +650.00%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.80
Upside: +1,401.13%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.30
Upside: +1,746.15%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.65
Upside: +579.25%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.26
Upside: +89,501.77%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.44
Upside: +43.35%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.48
Upside: +304.31%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.97
Upside: +529.72%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.23
Upside: +8,063.27%